1Department of Medicine, Graduate School, Jeju National University, Jeju, Republic of Korea
2Jeju Center for Infectious Disease Control and Prevention, Jeju, Republic of Korea
3Department of Preventive Medicine, Jeju National University College of Medicine, Jeju, Republic of Korea
© 2023 Korea Disease Control and Prevention Agency.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ethics Approval
This study was approved for exemption by the IRB of Jeju National University as a study utilizing secondary data (JJNU-IRB-2023-019).
Conflicts of Interest
The authors have no conflicts of interest to declare.
Funding
This study was supported by the 2023 Education, Research, and Student Guidance grant funded by Jeju National University.
Availability of Data
The datasets are not publicly available but are available from the corresponding author upon reasonable request.
Characteristic | Total (n=119) | 2015–2019 (n=21) | 2020–2022 (n=98) | p |
---|---|---|---|---|
Age (y) | 74.53±14.84 | 63.81±16.12 | 76.83±13.57 | <0.001*** |
Sex | 0.225 | |||
Male | 77 (64.7) | 16 (76.2) | 61 (62.2) | |
Female | 42 (35.3) | 5 (23.8) | 37 (37.8) | |
Hospital | <0.05* | |||
A | 102 (85.7) | 14 (66.7) | 88 (89.8) | |
B | 3 (2.5) | 2 (9.5) | 1 (1.0) | |
C | 10 (8.4) | 3 (14.3) | 7 (7.1) | |
D | 2 (1.7) | 1 (4.8) | 1 (1.0) | |
Other | 2 (1.7) | 1 (4.8) | 1 (1.0) | |
Diagnosis | <0.05* | |||
UAT | 91 (76.5) | 12 (57.1) | 79 (80.6) | |
UAT+culture | 3 (2.5) | 0 (0) | 3 (3.1) | |
UAT+PCR | 10 (8.4) | 3 (14.3) | 7 (7.1) | |
PCR | 15 (12.6) | 6 (28.6) | 9 (9.2) | |
Route | 0.817 | |||
Nosocomial | 19 (16.0) | 3 (14.3) | 16 (16.3) | |
Non-nosocomial | 100 (84.0) | 18 (85.7) | 82 (83.7) |
Year | Sex |
Age group (y) | ||
---|---|---|---|---|
Male | Female | <65 | ≥65 | |
2015 | 0.32 (0.01–1.80) | 0 | 0.19 (0.00–1.05) | 0 |
2016 | 1.26 (0.34–3.22) | 0 | 0.55 (0.11–1.61) | 1.16 (0.03–6.36) |
2017 | 0.61 (0.07–2.21) | 0.62 (0.08–2.24) | 0.18 (0.00–1.00) | 3.33 (0.68–9.62) |
2018 | 0.90 (0.19–2.63) | 0.30 (0.01–1.69) | 0 | 4.28 (1.15–10.82) |
2019 | 1.78 (0.65–3.88) | 0.60 (0.07–2.17) | 0.88 (0.28–2.04) | 3.09 (0.63–8.92) |
2020 | 3.25 (1.62–5.82) | 2.09 (0.84–4.31) | 0.88 (0.29–2.05) | 12.77 (6.70–21.53) |
2021 | 7.97 (5.25–11.59) | 3.56 (1.84–6.22) | 0.89 (0.29–2.06) | 31.72 (21.72–43.83) |
2022 | 6.78 (4.30–10.17) | 5.32 (3.16–8.41) | 1.60 (0.73–3.03) | 28.47 (19.33–39.90) |
Characteristic | Total (n=119) | 2015–2019 (n=21) | 2020–2022 (n=98) | p |
---|---|---|---|---|
Age (y) | 74.53±14.84 | 63.81±16.12 | 76.83±13.57 | <0.001 |
Sex | 0.225 | |||
Male | 77 (64.7) | 16 (76.2) | 61 (62.2) | |
Female | 42 (35.3) | 5 (23.8) | 37 (37.8) | |
Hospital | <0.05 |
|||
A | 102 (85.7) | 14 (66.7) | 88 (89.8) | |
B | 3 (2.5) | 2 (9.5) | 1 (1.0) | |
C | 10 (8.4) | 3 (14.3) | 7 (7.1) | |
D | 2 (1.7) | 1 (4.8) | 1 (1.0) | |
Other | 2 (1.7) | 1 (4.8) | 1 (1.0) | |
Diagnosis | <0.05 |
|||
UAT | 91 (76.5) | 12 (57.1) | 79 (80.6) | |
UAT+culture | 3 (2.5) | 0 (0) | 3 (3.1) | |
UAT+PCR | 10 (8.4) | 3 (14.3) | 7 (7.1) | |
PCR | 15 (12.6) | 6 (28.6) | 9 (9.2) | |
Route | 0.817 | |||
Nosocomial | 19 (16.0) | 3 (14.3) | 16 (16.3) | |
Non-nosocomial | 100 (84.0) | 18 (85.7) | 82 (83.7) |
Data are presented as crude incidence rate (95% confidence interval).
Data are presented as mean±standard deviation or UAT, urine antigen test; PCR, polymerase chain reaction.